Citation: “My Sterinity Nasal Platform: a Product of Collaboration”, ONdrugDelivery Online, March 19, 2026
SGD Pharma discusses the advantages and benefits of the company’s recent partnership with Prince Sterilization Services, with a focus on the first product platform developed based on this collaboration – the My Sterinity Nasal platform of Type I glass primary containers for sensitive, long-term nasal therapeutics. Additionally, SGD Pharma highlights its presence at DCAT Week 2026.
In the modern pharmaceutical industry, success increasingly depends on forming strong, reliable strategic partnerships across the supply chain. This theme is only increasing in relevance across the industry, with collaboration required between formulators, device designers, equipment manufacturers, material suppliers, fill-finish providers and more, each bringing their own specialities and experience. Today, finding the right partnerships can be the difference between success and failure. In this environment, SGD Pharma has enhanced its product offering by forming a Franco-American collaboration with Prince Sterilization Services (Montville, NJ, US).
STRATEGIC COLLABORATION FOR A CHANGING SUPPLY CHAIN
“As a manufacturer of moulded and tubular glass for pharmaceutical primary packaging, SGD Pharma has found a natural partner in Prince, enabling the company to validate its RTU Type I glass primary packaging solutions for the North American market.”
As a manufacturer of moulded and tubular glass for pharmaceutical primary packaging, SGD Pharma has found a natural partner in Prince, enabling the company to validate its ready-to-use (RTU) Type I glass primary packaging solutions for the North American market. The first tangible outcome of this collaboration is the My Sterinity Nasal platform, a new flexible cleaned vial range within SGD Pharma’s My Sterinity RTU platform, based on the company’s U-Save Type I vials, which are designed to support the expanding high-value nasal drug delivery sector.
The launch of the My Sterinity Nasal platform will be showcased at DCAT Week 2026, taking place on March 23–26, 2026, in New York, NY US. As the first platform built on the new collaboration between SGD Pharma and Prince, My Sterinity Nasal combines SGD Pharma’s Type I glass manufacturing capabilities with Prince’s expertise in sterilisation services for pharmaceutical products.
DESIGNED FOR HIGH-VALUE NASAL THERAPEUTICS
Initially available in 3.5, 7.5 and 10 mL formats in both clear and amber glass, My Sterinity Nasal vials offer key benefits for high-value nasal therapies:
- Controlled particulate and endotoxin levels for enhanced purity
- Biologically inert Type I sterile glass, which eliminates the need for preservatives, thereby reducing inflammation risk
- Validated sterility assurance
- Compatibility with standard preservative-free nasal pump systems
- Packaged in double-bagged trays for RTU presentations.
“The new My Sterinity Nasal vials support sensitive nasal drug delivery via high-quality primary packaging, which protects the drug and ensures stability, safety and efficacy.”
The new My Sterinity Nasal vials support sensitive nasal drug delivery via high-quality primary packaging, which protects the drug and ensures stability, safety and efficacy. Production of the My Sterinity Nasal range will take place at SGD Pharma’s flagship Saint-Quentin-La-Motte (SQLM) manufacturing facility in northern France, while Prince will provide washing, depyrogenation and sterilisation services in North America, ensuring a validated, regional supply chain qualified for US biopharmaceutical customers.
WHY GLASS IS GAINING GROUND IN NASAL DELIVERY
Historically, primary containers for nasal delivery have predominantly been made of plastic (around 88%). Glass, however, offers greater chemical inertness, barrier protection and long-term biocompatibility, which is critical for preserving product integrity, minimising adsorption and ensuring sterility in chronic-use therapies. Once focused on acute, rescue treatments, the nasal market is now expanding to include more advanced and long-term treatments for indications such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and depression. This new focus requires primary packaging that can offer sterility, consistency and precision dosing, making Type I glass the material of choice to safeguard the long-term therapeutic stability of these medications.
SGD Pharma’s collaboration with Prince marks an important milestone in the company’s innovation growth strategy for North America. The My Sterinity Nasal platform represents a major step forward in high-value nasal drug delivery, and the collaboration with Prince can provide SGD’s customers with immediate US-qualified capacity for biopharma customers scaling complex nasal therapy programmes – making it a validated supply chain ready to support qualification, clinical trials and commercial launch with speed and reliability.
SGD Pharma’s Type I glass expertise, combined with Prince’s quality-focused and flexible sterilisation platform presents a gold standard for sterile nasal packaging. Prince’s recent US qualification means that it can now deliver RTU, terminally sterilized My Sterinity Nasal vials in timelines that match domestic and international customer development cycles and exceed quality requirements.
“At DCAT 2026, alongside the launch of the My Sterinity Nasal platform, SGD Pharma will also highlight its growing portfolio of innovative glass packaging solutions designed to enhance drug integrity, patient safety and operational efficiency.”
SCALING SUPPLY AND SHOWCASING INNOVATION AT DCAT WEEK
At DCAT 2026, alongside the launch of the My Sterinity Nasal platform, SGD Pharma will also highlight its growing portfolio of innovative glass packaging solutions designed to enhance drug integrity, patient safety and operational efficiency. For example, SGD Pharma’s SEALIAN high-performance internal surface treatment that provides enhanced chemical durability and superior protection for sensitive drugs, and was recognised with the pharmaceutical Gold Award 2025 in the recent New Jersey Packaging Executive Club (Monroe Township, NJ, US) Packaging of the Year awards. Additionally, SGD Pharma’s DCAT 2026 showcase will include the company’s IDENCY premium vials, which offer a higher chemical and mechanical resistance than standard tubular vials and are designed to have the same outer diameter to enable easy integration with existing filling lines.
“As the industry adjusts to changing supply chain dynamics, the addition of My Sterinity Nasal to the company’s production lines is set to increase the manufacturing capacity for Type I moulded glass vials in the US market.”
SGD Pharma is a reliable, high-performing partner that is able to help its customers to scale, qualify or develop new products swiftly and with confidence. As the industry adjusts to changing supply chain dynamics, the addition of My Sterinity Nasal to the company’s production lines is set to increase the manufacturing capacity for Type I moulded glass vials in the US market. SGD Pharma’s Type I moulded glass portfolio offers:
- Exceptional Stability: Superior chemical durability and high hydrolytic resistance
- High Thermal Resistance: Low thermal expansion that provides extra protection during lyophilisation or autoclaving processes
- Mechanical Strength: Enhanced structural integrity, minimising the risk of breakage during filling and shipping
- Accelerated Timelines: With open capacity, SGD Pharma can offer shortened lead times and prioritised scheduling.
In SGD Pharma’s annual customer satisfaction survey, respondents rated SGD Pharma highly for its moulded glass products, with 97% of respondents satisfied and 70% citing its superior product quality. Furthermore, 98% of respondents stated they would work with the company in the future, demonstrating that SGD Pharma’s customers trust the company with their future vials business. At DCAT Week 2026, SGD Pharma’s global team will meet with partners and clients to explore collaborations and present these latest advancements in pharmaceutical glass packaging.